Investigational Drug Information for Proxalutamide
✉ Email this page to a colleague
What is the drug development status for Proxalutamide?
Proxalutamide is an investigational drug.
There have been 12 clinical trials for Proxalutamide.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 4th 2021.
The most common disease conditions in clinical trials are COVID-19, Severe Acute Respiratory Syndrome, and Coronavirus Infections. The leading clinical trial sponsors are Suzhou Kintor Pharmaceutical Inc,, Applied Biology, Inc., and Syneos Health.
There is one US patent protecting this investigational drug and four international patents.
Summary for Proxalutamide
| US Patents | 1 |
| International Patents | 4 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 20 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2021-08-04) |
| Vendors | 30 |
Recent Clinical Trials for Proxalutamide
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects | IQVIA Biotech | Phase 3 |
| A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects | Suzhou Kintor Pharmaceutical Inc, | Phase 3 |
| A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients | Syneos Health | Phase 3 |
Clinical Trial Summary for Proxalutamide
Top disease conditions for Proxalutamide
Top clinical trial sponsors for Proxalutamide
US Patents for Proxalutamide
International Patents for Proxalutamide
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Proxalutamide | Australia | AU2017321322 | 2036-08-29 | ⤷ Sign Up |
| Proxalutamide | Canada | CA3034257 | 2036-08-29 | ⤷ Sign Up |
| Proxalutamide | European Patent Office | EP3503898 | 2036-08-29 | ⤷ Sign Up |
| Proxalutamide | World Intellectual Property Organization (WIPO) | WO2018044817 | 2036-08-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
